<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01034332</url>
  </required_header>
  <id_info>
    <org_study_id>200707051M</org_study_id>
    <nct_id>NCT01034332</nct_id>
  </id_info>
  <brief_title>Paclitaxel/Cisplatin/Fluorouracil Followed by Paclitaxel/Cisplatin/Radiotherapy and Esophagectomy for Esophageal Cancer</brief_title>
  <official_title>A Phase II Study With One-cycle Weekly TP-HDFL Followed by Twice Weekly TP-CCRT and Esophagectomy for Locally Advanced Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that one-cycle induction chemotherapy may also help to identify
      chemo-responsive esophageal cancer patients who are highly treatable by definitive CCRT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that one-cycle induction chemotherapy may also help to identify
      chemo-responsive esophageal cancer patients who are highly treatable by definitive CCRT.in
      order to test this hypothesis, we thus propose this phase II clinical study to verify the
      role of &quot;response to one-cycle induction chemotherapy&quot;in the prediction of pathologic
      complete response rate to CCRT and tje outcomes for patients with loco-regional esophageal
      cancer.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2007</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>One-cycle induction chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP-HDFL, TP-CCRT, Esophagectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TP-HDFL,TP-CCRT, Esophagectomy</intervention_name>
    <description>To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.</description>
    <arm_group_label>One-cycle induction chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven esophageal cancer

          -  Locally advanced diseases T3 N0-1 M0; T1-3 N1 M0; T1-3 or N0-1 M1a

          -  Age ≥ 18 years old

          -  ECOG ≤ 2

          -  Creatinine &lt; 1.5 mg/dl AST, ALT &lt; 2.5 x upper normal limits Bilirubin &lt; 2.0 mg/dl

          -  WBC &gt; 4,000/μl or ANC&gt;2,000/μl

          -  Platelet &gt; 100,000//μl

          -  Informed consent

        Exclusion Criteria:

          -  Invasion to surrounding organs (T4 disease)

          -  Distant mets (except M1a)

          -  Prior thoracic irradiation

          -  Presence of other squamous cell carcinoma of aerodigestive way

          -  Symptomatic co-morbid diseases

          -  Previous malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Hung Hsu, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospita</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chih-Hung Hsu, M.D</last_name>
    <phone>886-2-23711174</phone>
    <phone_ext>7680</phone_ext>
    <email>chihhunghsu@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chin-Hung Hsu, MD</last_name>
      <phone>02-23123456</phone>
      <phone_ext>7680</phone_ext>
      <email>chihhunghsu@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2009</study_first_posted>
  <last_update_submitted>December 17, 2009</last_update_submitted>
  <last_update_submitted_qc>December 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chih-Hung Hsu / Department of Oncology</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Esophagectomy</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Induction chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

